Genmab A/S
DKFinancials
Valuation Metrics
Genmab A/S's Market Cap is $21.33B. At end of 2025 it was $18.98B. Ranked #573 of 3,121 in US market (top 18%), #178 of 1,463 on NASDAQ (top 12%), #28 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 11%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $21.33B | US#573/3,121 Sec#28/266 |
| Net Income | $788M | US#647/3,121 Sec#24/266 |
| Total Assets | $12.52B | US#864/3,121 Sec#27/266 |
| Net Assets | $5.96B | US#628/3,121 Sec#28/266 |
| Employees | 3,119 | US#1,459/3,121 Sec#33/266 |
| Value | ||
| P/E | 27.06x | US#1,477/3,121 Sec#40/266 |
| P/B | 3.58x | US#1,909/3,121 Sec#101/266 |
| P/S | 5.73x | US#2,394/3,121 Sec#85/266 |
| EV/EBITDA | 20.58x | US#1,910/3,121 Sec#50/266 |
| FCF Yield | 4.07% | US#1,609/3,121 Sec#50/266 |
| Profitability | ||
| ROE | 13.23% | US#1,029/3,121 Sec#41/266 |
| ROA | 6.30% | US#865/3,121 Sec#47/266 |
| Financial Health | ||
| Debt Ratio | 110.09% | US#1,194/3,121 Sec#172/266 |
| Total Debt | $5.27B | US#660/3,121 Sec#24/266 |
| FCF | $867M | US#644/3,121 Sec#29/266 |
| Cash | $1.50B | US#527/3,121 Sec#24/266 |
| Current Ratio | 2.46x | US#1,000/3,121 Sec#205/266 |
| Net Debt/EBITDA | 3.09x | US#1,640/3,121 Sec#65/266 |
| Performance | ||
| 1Y Return | 23.89% | US#1,077/3,121 Sec#149/266 |
| 1M Return | 1.85% | US#505/3,121 Sec#57/266 |
| From 52W High | -1.95% | US#139/3,121 Sec#13/266 |
| 1Y MDD | -32.51% | US#1,595/3,121 Sec#104/266 |
| Trading | ||
| Volume | 2,542,345 shares | US#651/3,121 Sec#63/266 |
| Trading Value | $89M | US#872/3,121 Sec#60/266 |
| Per Share | ||
| EPS | $1.28 | US#1,593/3,121 Sec#44/266 |
| BPS | $9.70 | US#1,868/3,121 Sec#71/266 |
Company Info
Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a robust pipeline of investigational medicines. These include GEN1047; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, both developed for solid tumors; Epcoritamab, in development for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37, aimed at hematological malignancies. Furthermore, the company has several products in Phase 2 clinical trials: Teclistamab for vaso-occlusive crises; Camidanlumab tesirine for Hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 for MM; PRV-015 for celiac disease; Mim8 for haemophilia A; and Lu AF82422 for multiple system atrophy disease. In addition to its clinical programs, Genmab is advancing approximately 20 active pre-clinical programs. Genmab fosters strategic collaborations to further its research and development efforts. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of differentiated mRNA-based antibody products and with AbbVie for the development of epcoritamab. Further alliances include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.